On May 8, 2026, Japan's Ministry of Economy, Trade and Industry approved and issued the revised edition of JIS T 0901:2026, General Requirements for Medical Sensors. For the first time, this standard adds a mandatory limit value of ≤0.5 ng/mL for the 24-hour leachate amount of nanoparticles in simulated body fluids for medical sensors such as pressure sensors and blood oxygen sensors that use nano-coatings or nanocomposite materials. The standard will be mandatorily implemented from October 1, 2026. Chinese manufacturers of medical sensors exporting to the Japanese market, material suppliers, and registration agencies need to pay close attention to this change, as it directly affects access to Japanese medical device registration qualifications.

Event Overview

On May 8, 2026, Japan's Ministry of Economy, Trade and Industry officially approved and issued the revised edition of JIS T 0901:2026, General Requirements for Medical Sensors. This version explicitly lists '24-hour leachate amount of nanoparticles in simulated body fluids ≤0.5 ng/mL' as a mandatory technical requirement, applicable to medical pressure sensors and blood oxygen sensors using nano-coatings or nanocomposite materials. The standard text has been made public, and the mandatory implementation date is October 1, 2026.

Which Segments Will Be Affected

Direct trading enterprises: mainly refers to companies exporting complete medical sensor products or modules to the Japanese market. Since JIS standards are an important compliance basis for Japanese medical device registration (PMDA review), failure to meet this nano-leaching limit will prevent products from passing type testing, thereby causing loss of registration eligibility. The impact will be directly reflected in suspended export orders, returned registration documents, or increased costs for resubmission testing.

Raw material procurement enterprises: includes companies procuring key materials such as nano-modified polymers, nano-silver antibacterial coatings, and functional fillers such as zinc oxide/titanium dioxide. The newly added limit value in the standard means that biocompatibility reports previously provided by existing material suppliers (such as ISO 10993-12 extraction tests) no longer automatically apply, and supplementary validation data for nanoparticle-specific testing (such as single-particle ICP-MS) is required.

Processing and manufacturing enterprises: involves companies engaged in process links such as coating of sensor-sensitive elements, packaging, and micro-nano structure processing. Nanomaterials may introduce interface instability risks during processing, resulting in uncontrollable leaching behavior; existing process parameters (such as curing temperature, time, and post-treatment cleaning methods) need to be reassessed for their impact on nanoparticle release.

Supply chain service enterprises: includes third-party institutions providing JIS standard interpretation, registration agency, and outsourced biocompatibility testing services. Their service content needs to be updated in sync with the clauses of JIS T 0901:2026, and in particular they need to have the capability for quantitative leaching testing of nanoparticles (such as sp-ICP-MS methods compliant with JIS Z 8901 or accredited under ISO/IEC 17025), otherwise it will be difficult to support clients' compliance filings.

What Key Points Should Relevant Enterprises or Practitioners Focus On, and How Should They Respond at Present

Confirm whether products fall within the scope of the new regulation

Check whether your medical sensors exported to Japan use nano-coatings (such as anticoagulant nano-silane layers), nanocomposite substrates (such as carbon nanotube-reinforced flexible substrates), or functional additives containing nanoscale materials (such as nano-silver conductive ink). If so, they fall under the mandatory scope and existing ISO 10993 reports cannot be relied upon as a substitute.

Initiate preliminary evaluation testing for material-level nano-leaching amounts

Give priority to selecting typical batch samples, conduct 24-hour extraction in simulated body fluids (such as PBS or extraction media specified in ISO 10993-12), and entrust laboratories with sp-ICP-MS or high-sensitivity TEM-EDS combined capabilities to perform quantitative analysis of nanoparticle concentration, comparing the result against the 0.5 ng/mL limit value. Avoid schedule delays caused by concentrated testing submissions before formal registration.

Sort out and update supply chain technical agreements

Request declaration documents from nanomaterial suppliers that comply with the requirements of JIS T 0901:2026, clearly specifying the nanoparticle release characteristics of their materials in simulated body fluids; add a clause on 'continuous compliance assurance for nano-leaching performance' to procurement agreements, and stipulate the allocation of batch verification responsibilities.

Reserve a window period for supplementary PMDA registration documents

For Japanese medical device registration applications that have already been submitted but not yet approved, proactively contact the registration agent to assess whether supplementary nano-leaching data is needed; new application projects must list the test item '24h nanoparticle leachate amount' separately in the type testing report, and the qualifications of the testing institution must be recognized by Japan's JNLA or accepted by PMDA.

Editorial Viewpoint / Industry Observation

Observably, this revision is not merely a technical update but signals Japan’s regulatory shift toward nano-specific biocompatibility governance in active medical devices. Analysis shows the 0.5 ng/mL limit is set at a level demanding analytical detection beyond conventional ICP-MS—indicating expectation of advanced characterization capability from manufacturers. From industry perspective, it functions more as an early-stage compliance gate than a matured enforcement framework: while mandatory from October 2026, official test protocols (e.g., exact simulation fluid composition, agitation conditions) remain pending JIS clarification. Current focus should be on readiness—not panic—since implementation hinges on verifiable measurement capacity, not just policy announcement.

Conclusion
This standard revision marks Japan's risk control of medical nanomaterials shifting from principle-based requirements to management through quantitative limit values. Its industry significance does not lie in immediately eliminating existing products, but in pushing export enterprises to establish full-chain safety assessment capabilities for nanomaterials. At present, it is more appropriate to understand it as a compliance preparation milestone for the fourth quarter of 2026, rather than an insurmountable technical barrier. Enterprises should respond systematically with three pillars: material measurability, process controllability, and data traceability.

Information source note
Main sources: official announcement on the website of Japan's Ministry of Economy, Trade and Industry (METI) and the text of JIS T 0901:2026 issued by the JIS Association.
Items requiring continued observation: whether Japan's PMDA will subsequently issue supporting guidance documents (such as Key Points for Biocompatibility Evaluation of Nano Sensors), JNLA's detailed accreditation rules for sp-ICP-MS testing institutions, and official interpretation of the specific preparation requirements for simulated body fluids.